Tampa、FLにおける卵巣がんの臨床試験
Tampaとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
被験者募集中第3相
- Research Site, Tampa
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Moffitt Cancer Center, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Moffitt Cancer Center, Tampa
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Moffitt, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Moffitt Cancer Center and Research Institute, Tampa
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- Tampa General Hospital Cancer Institute, Tampa
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
Clinical Pre-screening Protocol for Ovarian Cancer
被験者募集中観察研究
- Moffitt Cancer Center, Tampa
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
被験者募集中第1相
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
被験者募集中第1相
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
被験者募集中第1/2相
- Moffitt Cancer Center and Research Institute, Tampa
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
被験者募集中第2相
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Tampa
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #16, Tampa
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Tampaにおける他の研究
- 非小細胞肺癌51件の研究
- 乳がん43件の研究
- がん（全種類）39件の研究
- 大腸癌34件の研究
- 急性骨髄性白血病29件の研究
- 転移性癌29件の研究
- 肺がん29件の研究
- 膵臓がん26件の研究
- 悪性黒色腫19件の研究
- 骨髄異形成症候群19件の研究
- 前立腺がん18件の研究
- 心不全18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。